CorEvitas Acquires Pregnancy Data Registry Pregistry
This is the intelligence company's fifth acquisition.
CorEvitas announced the acquisition of Pregistry LLC, a company focused on safety studies during pregnancy.
Pregistry utilizes 70 pregnancy experts to provide reports and studies on healthy pregnancies and births. The group collects data based on clinical, safety, regulatory, marketing, and technology needs and is then shared with individuals, providers, and industry stakeholders. This information is reportedly used by doctors as part of their decisions on what medications and vaccines to prescribe.
In a press release, Dr. Diego Wysznski, founder and chief executive officer of Pregistry, said, “For the last eight years, Pregistry has been a leader in the design and execution of pregnancy exposure registries to fulfill global regulatory commitments, such as mandates from the FDA and the EMA, and other observational studies in the maternal health field, including the world's largest pregnancy registries on COVID-19 vaccines and Covid treatments.”
CorEvitas is an intelligence company to provides a syndicated network of registries. Pregistry is its fifth acquisition.
Continue reading this story here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
